Aprazer Healthcare Launched CAPEKAST

Posted by

Aprazer Healthcare

September 4, 2025

On October 31, 2020

Launch Date: 31/10/20

Aprazer Healthcare Launched CAPEKAST (Capecitabine) which is a medication indicated for the treatment of patients with metastatic breast cancer resistant to both paclitaxel and an anthracycline-containing chemotherapy regimen or resistant to paclitaxel and for whom further anthracycline therapy is not indicated.

Newer

Aprazer Healthcare Launched HQKAST

Older Aprazer Healthcare Launched LENVAKAST

Disclaimer: This medical information is intended only for healthcare professionals in India. The products discussed herein may have different product labeling in other countries. The information within this site is intended to provide balanced, scientific, and evidence-based answers to unsolicited medical questions. For full Prescribing Information including indications, contraindications, warnings, precautions, and adverse events, please submit a medical information request. This information is not intended as medical advice. Responsibility for patient care resides with the healthcare professional on the basis of his or her professional license, experience and knowledge of the patient. Products protected by valid patents are not offered for sale in countries where the sale of such products constitutes patent infringement. Any liability for patent infringement is at the buyer's risk. The website does not sell/purchase any medicine.